Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Cytokinetics, Lowers Price Target to $58

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $60 to $58.

byBenzinga Newsdesk

December 23, 2022

1 minute read

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $60 to $58.

Goldman Sachs Maintains Buy on Delek US Hldgs, Raises Price Target to $25

By Benzinga Newsdesk

Today, 5:11 AM

Goldman Sachs analyst Neil Mehta maintains Delek US Hldgs (NYSE:DK) with a Buy and raises the price target from $19 to $25.

Bloom Energy Q2 EPS $(0.23) Misses $(0.05) Estimate, Sales $228.50M Miss $232.44M Estimate

By Benzinga Newsdesk

Today, 5:11 AM

Bloom Energy (NYSE:BE) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.05) by 360 percent. This is unchanged from the same period last year. The company reported

MACOM Technology: Q3 Earnings Insights

By Benzinga Insights

Today, 5:11 AM

MACOM Technology Solns (NASDAQ:MTSI) reported its Q3 earnings results on Thursday, July 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

MTSI